东北制药(000597) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥1,940,260,731.63, a decrease of 17.58% compared to ¥2,354,060,515.14 in the same period last year[5] - Net profit attributable to shareholders was ¥57,633,861.05, down 17.72% from ¥70,050,130.06 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥29,840,934.15, a decline of 32.96% compared to ¥44,510,180.83 in the previous year[5] - The company's cash flow from operating activities was ¥94,887,495.36, a decrease of 17.02% from ¥114,351,104.00 in the same period last year[5] - Total operating revenue for Q1 2024 was CNY 1,940,260,731.63, a decrease of 17.5% compared to CNY 2,354,060,515.14 in Q1 2023[19] - Net profit for Q1 2024 was CNY 59,781,000.10, a decline of 18.4% from CNY 73,273,910.10 in Q1 2023[20] - Operating profit for Q1 2024 increased to CNY 117,668,309.64, up 10.4% from CNY 106,917,059.46 in Q1 2023[19] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.040, compared to CNY 0.049 in Q1 2023[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥15,606,158,257.65, an increase of 2.18% from ¥15,273,653,642.13 at the end of the previous year[5] - Current assets totaled CNY 10,257,304,938.05, up from CNY 9,783,060,044.00, indicating an increase of about 4.84%[15] - Total liabilities stood at CNY 10,374,476,331.11, up from CNY 10,114,911,352.16, representing an increase of about 2.57%[16] - The company's total equity reached CNY 5,231,681,926.54, compared to CNY 5,158,742,289.97, reflecting a growth of approximately 1.41%[16] - Short-term borrowings rose to CNY 1,570,629,999.99 from CNY 1,290,429,999.99, indicating an increase of about 22%[16] Research and Development - R&D expenses increased by 34% to ¥17,040,000 compared to the previous year, indicating a focus on innovation[8] - Research and development expenses for Q1 2024 were CNY 17,035,942.04, an increase of 34.5% from CNY 12,681,127.16 in Q1 2023[19] - The company is investing 200 million CNY in R&D for new drug development, focusing on oncology and chronic diseases[25] Cash Flow and Investments - Cash flow from operating activities for Q1 2024 was CNY 94,887,495.36, down 17.0% from CNY 114,351,104.00 in Q1 2023[22] - Total cash inflow from operating activities was CNY 1,795,609,240.28, down from CNY 2,250,571,821.35 in the previous year[22] - The company reported a net cash outflow from investing activities of CNY 49,863,803.84 in Q1 2024, compared to a net outflow of CNY 28,879,694.93 in Q1 2023[22] Market and Growth Outlook - Future outlook includes a projected revenue growth of 10-15% for the full year 2024, driven by new product launches[25] - Market expansion plans include entering two new provinces in China by Q3 2024, aiming for a 5% market share increase[25] - A strategic acquisition of a local biotech firm is expected to enhance the product pipeline and increase market competitiveness[25] - The company plans to launch three new products in Q2 2024, targeting a combined revenue contribution of 300 million CNY[25] - Cost reduction initiatives are projected to save 50 million CNY annually, improving overall profitability[25] - The company aims to enhance digital marketing efforts, expecting a 30% increase in online sales channels by the end of 2024[25] Customer and Revenue Metrics - The company achieved a net profit margin of 12%, reflecting a 2% improvement compared to the previous quarter[25] - User data indicated a 20% growth in the customer base, totaling 5 million active users by the end of Q1 2024[25] Inventory and Contract Liabilities - The company reported a 40% decrease in contract liabilities, totaling ¥79,240,000, due to reduced advance payments[8] - The total inventory increased to CNY 1,433,135,077.17 from CNY 1,364,090,227.71, showing a growth of about 5.06%[15] - The company reported a decrease in contract liabilities from CNY 131,168,024.29 to CNY 79,237,698.60, a reduction of approximately 39.6%[16]